Platelet count control in immune thrombocytopenic purpura patient: optimum romiplostim dose profile

Tsai, Chi-Ying; Bussel, James B.; Imahiyerobo, Allison; Sandler, Stanley I.; Ogunnaike, Babatunde A.

doi:10.3182/20140824-6-za-1003.00474

Cited by 2 publications

References 6 publications

(11 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

Is There a Role for Biweekly Romiplostim in the Management of Chronic Immune Thrombocytopenia (ITP)? A Report of Three Cases

Rooprai

Khamisa

2018

Case Reports in Hematology

View full text Add to dashboard Cite

Romiplostim is a peptibody, which stimulates platelet production by a mechanism similar to that of endogenous thrombopoietin. It has an established indication as second-line therapy in patients with chronic immune thrombocytopenia (ITP). The agent is typically administered weekly; however, there are instances where a biweekly (i.e., alternate week) dosing may be feasible in a select group of patients. We conducted a retrospective case review to evaluate the efficacy and safety of biweekly administration of romiplostim in maintaining a platelet count of >30 × 109/L in three patients with chronic ITP. Treatment was started with a weekly injection (1 µg/kg) with a dose escalation to achieve a platelet count >30 × 109/L. Once stable on weekly romiplostim, these patients received biweekly administration. No bleeding complications were noted during biweekly dosing for these patients. The current findings suggest that lengthening the dose interval of romiplostim is feasible in select patients with chronic ITP to maintain stable platelet counts. Additional studies are therefore warranted to further evaluate biweekly dosing for romiplostim to increase convenience and decrease costs for patients with chronic ITP.

show abstract

Is There a Role for Biweekly Romiplostim in the Management of Chronic Immune Thrombocytopenia (ITP)? A Report of Three Cases

Rooprai

Khamisa

2018

Case Reports in Hematology

View full text Add to dashboard Cite

show abstract

Design of Drug Dosage Regimen (DDR) for Immune Thrombocytopenic Purpura (ITP) Patients Using Control Theory Concepts

Rajkumar

Narayanan

Sivakumaran

2022

Advances in Medical Technologies and Clinical Practice

View full text Add to dashboard Cite

In this chapter, an optimal drug dosage regimen is designed by incorporating the standard treatment guidelines in terms of average and safe limits of drug dosage for immune thrombocytopenic purpura patients (ITP). If constant drug dosage is administered with fixed dosing, the interval leads to sustained oscillations of platelet count values with higher magnitude. Moreover, the amount of dose utilized for the treatment is also high. This leads to undesirable consequences which are dangerous to patients. Hence, a composite framework is essential to obtain optimal drug dosage for specific ITP patients. This chapter presents the potential benefits of the pharmacokinetic-pharmacodynamic (PK/PD) model of ITP patients and its applicability to obtain the optimum dosage profile using linear control theory in line with standard guidelines. Prediction of dosage interval is made for a specific patient using this PK/PD model. And this information is given to the controller framework as sampling time.

show abstract

Platelet count control in immune thrombocytopenic purpura patient: optimum romiplostim dose profile

Cited by 2 publications

References 6 publications

Is There a Role for Biweekly Romiplostim in the Management of Chronic Immune Thrombocytopenia (ITP)? A Report of Three Cases

Is There a Role for Biweekly Romiplostim in the Management of Chronic Immune Thrombocytopenia (ITP)? A Report of Three Cases

Design of Drug Dosage Regimen (DDR) for Immune Thrombocytopenic Purpura (ITP) Patients Using Control Theory Concepts

Contact Info

Product

Resources

About